Geode Capital Management
XBIO icon

Geode Capital Management’s Xenetic Biosciences XBIO Stock Holding History

Geode Capital Management’s Portfolio XBIO Stock Details XBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57.5K Buy
21,441
+7,860
+58% +$19.4K ﹤0.01% 4280
2025
Q4 		$29.5K Buy
13,581
+2,897
+27% +$9.24K ﹤0.01% 4332
2025
Q3 		$34.2K Buy
10,684
+206
+2% +$672 ﹤0.01% 4364
2025
Q2 		$41.1K Sell
10,478
-475
-4% -$1.37K ﹤0.01% 4253
2025
Q1 		$28.6K Sell
10,953
-936
-8% -$3.66K ﹤0.01% 4287
2024
Q4 		$47.9K Hold
11,889
– – ﹤0.01% 4249
2024
Q3 		$52.1K Sell
11,889
-99
-0.8% -$390 ﹤0.01% 4261
2024
Q2 		$50.3K Buy
11,988
+990
+9% +$4K ﹤0.01% 4277
2024
Q1 		$41.5K Hold
10,998
– – ﹤0.01% 4359
2023
Q4 		$39.5K Hold
10,998
– – ﹤0.01% 4406
2023
Q3 		$53.8K Buy
+10,998
New +$45.9K ﹤0.01% 4404
2023
Q2 		– Sell
-9,155
Closed -$37.7K – 4783
2023
Q1 		$37.7K Sell
9,155
-79
-0.9% -$383 ﹤0.01% 4582
2022
Q4 		$26K Sell
9,234
-26
-0.3% -$114 ﹤0.01% 4729
2022
Q3 		$49K Hold
9,260
– – ﹤0.01% 4770
2022
Q2 		$74K Buy
9,260
+165
+2% +$1.33K ﹤0.01% 4683
2022
Q1 		$92K Hold
9,095
– – ﹤0.01% 4689
2021
Q4 		$117K Sell
9,095
-1,320
-13% -$21.1K ﹤0.01% 4673
2021
Q3 		$213K Buy
10,415
+5,364
+106% +$146K ﹤0.01% 4422
2021
Q2 		$103K Buy
5,051
+1,925
+62% +$38.8K ﹤0.01% 4551
2021
Q1 		$68K Buy
3,126
+1,808
+137% +$47.6K ﹤0.01% 4365
2020
Q4 		$26K Buy
+1,318
New +$16K ﹤0.01% 4231

Other funds holding XBIO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
DWM
Darwin Wealth Management Tampa, Florida $365M AUM 22.69% 1-Year Est. Return

Geode Capital Management's XBIO Position: Q1 2026 in Review

Geode Capital Management increased its Xenetic Biosciences (XBIO) stake by 58% in Q1 2026, buying an estimated $19.4K and bringing the position to 21,441 shares worth $57.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4280.

Geode Capital Management first reported a position in XBIO in Q4 2020 and has held it in 21 quarters since. The position peaked at $213K in Q3 2021. 6 funds tracked by Wall St. Rank hold XBIO as of Q1 2026.

  • Geode Capital Management held 21,441 shares of Xenetic Biosciences worth $57.5K as of Q1 2026.
  • Geode Capital Management bought 7,860 Xenetic Biosciences shares in Q1 2026, an estimated $19.4K.
  • Xenetic Biosciences made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4280 holding.
  • Geode Capital Management first reported a position in Xenetic Biosciences in Q4 2020 and has held it in 21 quarters since.
  • Geode Capital Management's Xenetic Biosciences position peaked at $213K in Q3 2021.
  • 6 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.